1. Home
  2. SLRC vs AVXL Comparison

SLRC vs AVXL Comparison

Compare SLRC & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRC
  • AVXL
  • Stock Information
  • Founded
  • SLRC 2007
  • AVXL 2004
  • Country
  • SLRC United States
  • AVXL United States
  • Employees
  • SLRC N/A
  • AVXL N/A
  • Industry
  • SLRC Finance/Investors Services
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SLRC Finance
  • AVXL Health Care
  • Exchange
  • SLRC Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • SLRC 889.2M
  • AVXL 956.7M
  • IPO Year
  • SLRC 2010
  • AVXL N/A
  • Fundamental
  • Price
  • SLRC $16.07
  • AVXL $8.72
  • Analyst Decision
  • SLRC Hold
  • AVXL Strong Buy
  • Analyst Count
  • SLRC 6
  • AVXL 2
  • Target Price
  • SLRC $16.13
  • AVXL $44.00
  • AVG Volume (30 Days)
  • SLRC 196.3K
  • AVXL 944.5K
  • Earning Date
  • SLRC 11-05-2025
  • AVXL 08-12-2025
  • Dividend Yield
  • SLRC 10.22%
  • AVXL N/A
  • EPS Growth
  • SLRC N/A
  • AVXL N/A
  • EPS
  • SLRC 1.63
  • AVXL N/A
  • Revenue
  • SLRC $222,445,000.00
  • AVXL N/A
  • Revenue This Year
  • SLRC N/A
  • AVXL N/A
  • Revenue Next Year
  • SLRC $0.23
  • AVXL N/A
  • P/E Ratio
  • SLRC $9.86
  • AVXL N/A
  • Revenue Growth
  • SLRC N/A
  • AVXL N/A
  • 52 Week Low
  • SLRC $13.64
  • AVXL $5.03
  • 52 Week High
  • SLRC $17.94
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • SLRC 40.78
  • AVXL 39.75
  • Support Level
  • SLRC $15.86
  • AVXL $8.85
  • Resistance Level
  • SLRC $16.15
  • AVXL $9.69
  • Average True Range (ATR)
  • SLRC 0.20
  • AVXL 0.55
  • MACD
  • SLRC -0.08
  • AVXL -0.03
  • Stochastic Oscillator
  • SLRC 20.89
  • AVXL 12.24

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: